Kadmon Pharmaceuticals

Mr. Nima Moayer
Senior Director, Marketing
New York,  NY 
United States
  • Booth: 417

Thanks for visiting and learning more about Kadmon.

Kadmon is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Out clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. On July 16, 2021 the U.S. FDA approved REZUROCK™ (belumosudil) 200 mg tablets daily for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

Brands: REZUROCK™ (belumosudil)

Send email to this exhibitor 

Type your information and click "Send Email" to send an email to this exhibitor. To clear without saving, click "Reset".